JUMISC

NANBIOSIS ICTS invites groups and companies to discuss Smart Biomaterials and devices for Drug Delivery

On February 22nd, the National School of Health of the Carlos III Health Institute hosted the forum on Smart Biomaterials and biomedical devices for applications in drug delivery and regenerative medicine, organized by the ICTS Nanbiosis, an infrastructure shared by the CIBER-BBN and the Center of Minimally Invasive Surgery Jesus Usón (CCMIJU). This is the first groups/companies meeting organized by Nanbiosis, in which about 70 B2B meetings were held.

The meeting brought together about 40 participants from 14 research groups (from the CIBER-BBN and the CCMIJU) and 10 companies, which discussed the latest advances in the research lines developed by the groups and platforms of Nanbiosis and on the needs and demands of the industry in smart biomaterials and devices for targeted drug delivery and regenerative medicine.

Jesus Izco, Coordinator of Nanbiosis, presented the new “Cutting-Edge Biomedical Solutions“, soon available on the ICTS website. These are integrated solutions to advanced challenges in nanomedicine, biomaterials, medical device, and diagnostic that can be developed by several units under a one-stop shop model, optimized with the experience and scientific and technical knowledge of the research groups of excellence that manage the involved units. Some of the Cutting-edge biomedical solutions presented in the meeting were preclinical validation of biomaterials, mechanical and surface characterization, biocompatibility and studies of biofilm formation and infections.

The CIBER-BBN prsentations were: “Instructive materials for regenerative medicine” by Miguel Ángel Mateos (NANBIOSIS U5 IP: Elisabeth Engel); “Molecular biomaterials for drug delivery and biomedical applications” byNathaly Veronica Segovia (NANBIOSIS U6 / IP Jaume Veciana and Nora Ventosa); “Advances with micro-nano technologies for in vitro devices and point of care” by Rosa Villa (NANBIOSIS U8 ); “Development of new dosage forms for advanced therapies based on new biomaterials” by José Luis Pedraz (NANBIOSIS U10); “Contact lenses functionalized for the prevention of corneal infections” by Jordi Esquena (NANBIOSIS U12 / IP Carlos Rodríguez); “Combined in-silico and in-vitro models of the cell microenvironment and drug delivery effects in cancer and tissue engineering applications” by Fany Peña (NANBIOSIS U13 / IP Miguel Á. Martínez); “Surface of the biomaterial: the first contact with our body” by Marisa González (NANBIOSIS U16 ); “Use of biomaterials for the repair of soft tissue defects” by Bárbara Pérez Khöler (NANBIOSIS U17 / IP J M. Bellón and Gemma Pascual); “Controlled release systems based on mesoporous materials with molecular doors for applications in therapy and diagnosis” by Ramón Martínez Máñez (NANBIOSIS U26); “New intelligent devices and biomaterials for the treatment of pathologies of the retina and the nervous system” (Eduardo Fernández); and “Near-infrared responsive scaffolds for biomedical applications” (Nuria Vilaboa).

On the part of the CCMJU, the presentations were the following: “Application of Mesenchymal Stem Cells in preclinical models for surgical and cardiovascular research” by Javier García Casado (NANBIOSIS U14); “Regenerative medicine in animal models of cutaneous healing and diabetic models” by Beatriz Moreno (NANBIOSIS U19); “Preclinical studies of biomaterials” by Idoia Díaz-Güemes (NANBIOSIS U21 /IP: FM Sánchez Margallo); “Porcine model of myocardial infarction as a translational research platform in regenerative medicine” by Verónica Crisóstomo (NANBIOSIS U24).

In the turn of the companies, they presented some collaboration opportunities AJL, i-Vascular, Praxis Pharmaceutical, Technical Proteins Nanobiotechnology and REGEMAT 3D; and they also participated in the Rovi, Viscofan, Biomag and Biogelx Laboratories forum.

These meetings, where links are established between research groups and companies, address issues of business and scientific interest, allowing direct contacts between researchers and business managers.

• Read More

The Minimally Invasive Surgery Centre uses HoloLens glasses for medical training and surgical assistance in urology

The Minimally Invasive Surgery Centre, partner of NANBIOSIS, has developed a software platform to apply mixed reality to medical training and surgical assistance. This will enable the creation of new and more realistic scenarios for medical training and improve surgical results.

The Minimally Invasive Surgery Centre (CCMIJU) uses mixed reality technology, by means of the Microsoft’s HoloLens glasses, to help train future healthcare professionals and provide an assistance tool for complex surgeries.

The institution located in Cáceres has begun using the mixed reality glasses, whose technology combines virtual reality with augmented reality, with the aim of developing, on the one hand, a medical training platform for the anatomy of the pelvic floor, and on the other, a tool for surgical assistance during renal tumor resection procedures.

The use of this technology will benefit both medical students and residents, as well as surgeons. For the former, a software application has been developed and integrated in the HoloLens glasses, that will allow them to visualize and interact with the human anatomy of the pelvis -with and without pathologies- both at muscular, vascular, bone and nervous systems levels. This will facilitate its translation to the real medical practice.

As for the surgeons, this technology will provide access to preoperative studies and real 3D models of the patient in the form of virtual holograms, facilitating the surgical planning and assistance during the abovementioned renal interventions.

The software, developed entirely at the CCMIJU, is in its validation phase in operating rooms. For the first time, and using their own 3D anatomical models, this type of technology is being used for training on the pelvic floor anatomy and for surgical assistance in renal tumor resections.

This R&D line arises from public-private cooperation. The CCMIJU’s team, led by Dr. Francisco Miguel Sánchez Margallo, Scientific Director of this institution, consists of engineers and staff of the Interactive 3D Unit of the Centre who work together with the company CIBEX on the development of new surgical applications. This alliance will enable healthcare professionals to use this emerging technology in challenging surgical interventions and carry out more effective and safe surgeries.

• Read More

JUMISC, partner of NANBIOSIS, represents Spain in a European network of 22 countries

The Jesús Usón Minimally Invasive Surgery Centre (JUMISC), partner of NANBIOSIS toguether with CIBER-BBN, leads a multidisciplinary European research network to improve present urinary stents and prevent their causes of failure.

The idea of creating the network was born from a research, started in 1999 by Doctor Soria, Researcher-Coordinator of the Endoscopic Surgery Area at the JUMISC and the promoter of the mentioned network, representing Spain.

His proposal has been supported by the European and Spanish Urology Association, and funded by the Horizon 2020 Program-Cost Actions (European Cooperation in Science and Technology)

The focus of this Action is to create a multidisciplinary team to identify the problems concerning the urinary stents (design, composition, biomaterial applications, coatings, incrustation, etc.) and to promote future research on this field. In this way, the network will try to reduce adverse effects provoked by the present stents.

This European network (2017-2021), coordinated by Dr. Soria, the Chair of the Action, is composed by 22 European countries and other proposals coming from USA, Japan, South Korea, Israel, Canada, Russia, India and it is open to other invited countries to cooperate inside the organised working groups.

This action will provide, during the next 4 years, an extensive and interdisciplinary R&D program to discover the causes of failure of the present stents and will propose cooperative work in urology and bioengineering field.

This proposal, an initiative of the JUMISC, leaded by Doctor Sánchez Margallo, will contribute to improve healthy-quality of patients, reduce in health care costs, and increase the competitiveness of the European medical device industry.

• Read More

II MASTER ON ENDOSCOPY AND MINIMALLY INVASIVE SURGERY IN SMALL ANIMALS (CEyCMI). EXTRAORDINARY DEADLINE FOR ADMISSIONS

A new extraordinary deadline for admissions to the II MASTER ON ENDOSCOPY AND MINIMALLY INVASIVE SURGERY IN SMALL ANIMALS has been set up, from 1^st to 14th September. It is organised in collaboration with the Extremadura University ant takes place in Jesús Usón Minimally Invasive Surgery Centre as affiliated entity, offering 60 ECTS-credits.Necessary requirements include having a Veterinary studies degree and a B1 English Certificate. The Master will be held during the academic calendar 2017-2018, according to the established program, that will promote the interaction with the students via an on-line training platform, the direct contact with professors and experts, as well as offering an open material repository.

The Master consists on 4 hands-on training sessions at the JUMISC’s, an external stage in one of our partners centre and the Master’s degree final project.

Further info: www.ccmijesususon.com/ceycmi2017

• Read More

JUMISC awarded with the Prize to the Best Research Practice

Last Friday, May 5, JUMISC was awarded in the 1st edition of Extremadura Health Prices, event organised by Sanitaria 2000, text-editor of the Redacción Médica, the most famous and specialised newspaper in its sector.

The contribution of the Extremadura Health Service and the regional health sector were awarded between the 56 nominations included in 14 categories. JUMISC obtained the award of “Best Research Practice”.

The event was held in the convent of San Juan de Dios, in Olivenza-Badajoz, and gathered the JUMISC’s Scientific Director, Mr. Sánchez Margallo (on behalf of the institution), together with other authorities and health managers.

A prestigious jury decided about winners in accordance to the following classification: The best public hospital, the best hospital service, the best physician, the best primary healthcare, the best health administration, the best research practice, the best private health institution, the best nursery practice, the best social responsibility for health, the best scientific society, the best technological contribution, the best association of patients and the best chemistry practice.

• Read More

10th Anniversary of the New Minimally Invasive Surgery Centre (JUMISC)

Next Friday, 21^st April, we celebrate the 10^th Anniversary of the new JUMISC, betting on training and on research and development activities.

In its ten years of background we emphasize the following figures:

500 trained physicians,
160 training activities per year
More than 100 R&D projects with 7.930.800 € funding
17 patents,
The creation of a spin-off,
The development of 25 apps,
More than 623 scientific collaborators,
500 visits received from more than 500 institutions.

10 years full of training courses and European R&D projects. We are so proud for the promotion and creation of the Clúster Sociosanitario of Extremadura (Health Cluster), for obtaining the Good Laboratory Practice to carry out preclinical trials, for launching a Program of training on Assisted Reproduction, for creating a 3D Department to develop apps, for being included as ICTS in the Spanish Map of Singular Facilities and in the CIBER-CV (Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares).

Jesus Usón Minimally Invasive Surgery Centre (JUMISC), one of NANBIOSIS partners together with CIBER-BBN, is a multidisciplinary institution devoted to research and innovation in health sciences.

Further info about our achievement in:

http://10aniversario.ccmijesususon.com/

• Read More

A photonic endoscope to improve the colon cancer diagnosis

Last 18th and 19th January, the Jesús Usón Minimally Invasive Surgery Centre attended the kick of meeting of the European project “Multimodal highly-sensitive PhotonICs endoscope for improved in-vivo COLOn Cancer diagnosis and clinical decision support” (PICCOLO, the English abbreviation), held in Bilbao.

This project proposes a new compact, hybrid and multimodal photonics endoscope based on Optical Coherence Tomography (OCT) and Multi-Photon Tomography (MPT) combined with fluorescence technology.
Colorectal cancer represents around one tenth of all cancers worldwide. Early and accurate diagnosis and precise intervention can increase cure rate up to 90%.

The multidisciplinary team, composed by Tecnalia Foundation, the project coordinator, and other eight European partnerscoming from Italy, UK, Ireland, Germanyand Spain, joins to work together in this ambitious project, financed by the UE Horizon2020 Programme. PICCOLO is focused to develop an innovative endoscope that will provide gastroenterologists immediate and detailed in situ identification of colorectal neoplastic lesions and facilitate accurate and reliable diagnostics.

The consortium comprises the whole value chain including pre-clinical and clinical partners, technology providers, photonics SMEs and endoscopy market Leader Company.

This project has received funding from the European Union’s Horizon 2020 research and innovation Programmeunder Grant Agreement No. 732111.

This information reflects only the institution’s view, so the Agencies and the Commission are not responsible for any use that may be made of the information it contains.

Nanbiosis - A photonic endoscope to improve the colon cancer diagnosis

• Read More

Nanbiosis new ICTS incorporation

The new map of Scientific and Technological Infrastructures (ICTS), was updated by the Council for Science Policy, Technology and Innovation last 7^th of October, 2014, which incorporated The Integrated Infrastructure on Production and Characterization of Nanomaterials, Biomaterials and Systems in Biomedicine (NANBIOSIS) . The new ICTS is integrated by the CIBER-BBN and the Center for Minimally Invasive Surgery Jesus Uson (JUMISC).

Pablo Laguna, scientific director of the CIBER-BBN noted that “this recognition is the result of efforts of both institutions to try to provide research services of high quality and added value, usually high-cost equipment, which is available to the scientific community, giving them greater and better use and avoiding costly and not always necessary redundancies. Furthermore, the fact that these infrastructures are coordinated by experts in their subjects, makes the scope of these infrastructures to exceed the national territory to become an actor at international level “.

The research infrastructure is aimed at medical applications and tries to provide a complete service and easy access through a “single contact point”, which includes the design, production of biomaterials and nanomaterials characterization of these materials, tissues , medical and systems from a physical, chemical, functional, toxicological and biological point of view including preclinical validation.

NANBIOSIS’ Units are located in Zaragoza, Badajoz, Barcelona, Caceres, Madrid, Valencia and Álava. Provides personnel and cross-cutting equipment in all the units in which infrastructure is organized, with dedication to service to the entire scientific community.

The new Spanish map of ICTS has 29 infrastructures and has been updated taking into account criteria of highest scientific quality, technology and innovation, subjecting candidates to a rigorous process of independent evaluation.n (check ICTS map)

The so-called singular scientific and technical infrastructures (ICTS) are large installations, resources, facilities and services, unique in its kind, that are dedicated to cutting edge and high quality research and technological development, as well as to promote exchange, transmission and preservation of knowledge, technology transfer and innovation. Its main objective is provision to national and international scientific, technological and industrial community of essential scientific and technical infrastructure for the development of a scientific and technological research unique or exceptional in its genre, with a very high cost of investment and maintenance and whose importance and strategic nature justifies their availability for the whole R + D + i collective. Therefore, the ICTS are infrastructures of PUBLIC ownership, are UNIQUE and OPEN to competitive access to users of the whole research community in the public and private sector..

• Read More

JUMISC works in a R&D project: Stem cell therapy for cartilage repair

The Jesús Usón Minimally Invasive Surgery Centre (JUMISC) works in a R&D project, that aims to find a biomaterial that will help injured cartilage to repair.

The targets of the project are to design a biomaterial that could be implanted in the human body and to apply it in the osteoarticular pathology treatment. The main goal is that people who suffer from osteoarthritis, a pathology that damages the cartilage joint, get better through a minimally invasive surgery procedure.

The consecutive phases of the project will be the development of the biomaterial, tests in vitro and the preclinical trials, as testing in pig animal model.

After finishing these phases, vet professionals will monitore them, through imaging and surgery techniques, using MRI scan and arthroscopy, to study the evolution of the injuries.

At the end of the R&D project, those injured joints where the biomaterial was implanted, will be analyzed through microscopy techniques, and vet professionals will determine if the cartilage has improved.

JUMISC and the partners of the project (enterprises, hospitals and others) are focused on testing that the treatment is safe and effective, and from this premise we will be ready to start clinical trials in hospitals, in order to demonstrate the effectiveness of the biomaterial in patients.

JUMISC- Arthroscopy -Stem cell therapy for cartilage repair

• Read More

You are here : Home / JUMISC (Page 9)